ID: ALA3357596

Max Phase: Preclinical

Molecular Formula: C20H21BrN4O5

Molecular Weight: 477.32

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NC[C@@H]1CC(Br)=NO1)[C@@H]1C[C@@H](O)CN1C(=O)OCc1cnc2ccccc2c1

Standard InChI:  InChI=1S/C20H21BrN4O5/c21-18-7-15(30-24-18)9-23-19(27)17-6-14(26)10-25(17)20(28)29-11-12-5-13-3-1-2-4-16(13)22-8-12/h1-5,8,14-15,17,26H,6-7,9-11H2,(H,23,27)/t14-,15+,17+/m1/s1

Standard InChI Key:  SNTBGRNJNXGKHI-VYDXJSESSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 477.32

Molecular Weight (Monoisotopic): 476.0695

AlogP: 1.92

#Rotatable Bonds: 5

Polar Surface Area: 113.35

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 4.07

CX LogP: 0.96

CX LogD: 0.96

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.68

Np Likeness Score: -0.82

References

1. Klöck C, Herrera Z, Albertelli M, Khosla C..  (2014)  Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.,  57  (21): [PMID:25333388] [10.1021/jm501145a]

Source

Source(1):

• Scientific Literature